Adding Tirzepatide to Basal Insulin Cuts HbA1c in Poorly Controlled T2D
(MedPage Today) -- HAMBURG, Germany -- Adding weekly tirzepatide (Mounjaro) to basal insulin reduced HbA1c in patients with poorly controlled type 2 diabetes compared with adding three-times-daily insulin lispro, the phase IIIb SURPASS-6 trial...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Germany Health | Heart | Humalog | Insulin